Multiple Sclerosis News TodayGut Bacteria at MS Diagnosis Offer Early Clues to Disease Course

⚠️ Observational Biomarker Study

The relationship between the gut microbiome and multiple sclerosis has attracted increasing attention, but most prior studies evaluated patients with established disease or exposure to disease-modifying therapies that can alter microbial composition. This multicenter Italian observational study examined treatment-naive patients at disease onset to determine whether gut bacterial signatures correlated with prognostic MRI findings and subsequent disease activity.

Researchers analyzed stool samples from 53 adults with newly diagnosed MS and 55 healthy controls. Significant microbiome differences were identified between groups, and several bacterial species were associated with MRI characteristics historically linked to less favorable outcomes.

Clinical Considerations

• The study included 53 newly diagnosed MS patients and 55 healthy controls recruited across four centers.
• Participants had not yet received disease-modifying therapy and had no recent antibiotic exposure, reducing major microbiome confounders.
• Overall gut microbiome composition differed significantly between MS patients and healthy controls.
• Forty-six bacterial species were associated with at least one unfavorable MRI feature, including high lesion burden, spinal cord lesions, infratentorial lesions, and inflammatory activity.
• Reduced abundance of certain Bacteroides species was associated with both MS diagnosis and MRI findings linked to poorer prognosis.
• Increased abundance of species including Barnesiella, Romboutsia ilealis, Clostridium innocuum, and Ruminococcus correlated with MRI features suggesting greater disease burden.
• Microbiome-based clustering identified two clinically distinct patient groups at diagnosis.
• One group demonstrated a trend toward less disease progression over 12 months, but this difference did not reach statistical significance.

Practice Applications

• Recognize that gut microbiome composition remains an active area of MS biomarker research but is not yet ready for routine clinical prognostic use.
• Interpret microbiome findings as hypothesis-generating associations rather than validated predictors of disease course.
• Continue established risk assessment using clinical presentation, MRI burden, spinal cord involvement, disease activity, and guideline-supported prognostic factors.
• Monitor emerging evidence regarding microbiome-directed diagnostics and therapeutics, particularly prospective studies validating prognostic performance.
• Avoid using microbiome testing to guide treatment intensity or disease-modifying therapy selection outside research settings.